AnaptysBio, Inc. (LON: 0HFQ)

Market Cap	399.75M
Revenue (ttm)	42.66M
Net Income (ttm)	-123.60M
Shares Out	n/a
EPS (ttm)	-4.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,342
Average Volume	735
Open	16.83
Previous Close	16.76
Day's Range	16.05 - 17.00
52-Week Range	10.05 - 32.95
Beta	n/a
RSI	49.50
Earnings Date	Mar 6, 2025

About AnaptysBio

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and I...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 117
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HFQ

Financial Performance

In 2023, AnaptysBio's revenue was $17.16 million, an increase of 66.78% compared to the previous year's $10.29 million. Losses were -$163.62 million, 27.1% more than in 2022.

Financial numbers in USD